89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors [Yahoo! Finance]
89bio, Inc. (ETNB)
Last 89bio, inc. earnings: 3/18 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024. Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman of the Board of Alumis Therapeutics. “As 89bio executes on its ongoing Phase 3 programs for pegozafermin, this is an opportune time to add an industry leader like Martin to our board,” said Rohan Palekar, Chief Executive Officer of 89bio. “Martin's impressive track record for building and leading companies through commercialization will be invaluable to us at this stage in our development, and we look forward to leveraging his extensive experience and strategic insight to deliver on the full potential of pegozafermin.” Mr. Babler brings over 30 years of pharmaceutical and biotech experience. Prior to his role at Alumis The
Show less
Read more
Impact Snapshot
Event Time:
ETNB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETNB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETNB alerts
High impacting 89bio, Inc. news events
Weekly update
A roundup of the hottest topics
ETNB
News
- 89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $30.00 price target on the stock.MarketBeat
- 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of DirectorsGlobeNewswire
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- 89bio, Inc. (NASDAQ: ETNB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $29.00 price target on the stock.MarketBeat
ETNB
Earnings
- 11/8/23 - Beat
ETNB
Sec Filings
- 4/23/24 - Form 3
- 4/19/24 - Form ARS
- 4/17/24 - Form DEFA14A
- ETNB's page on the SEC website